AVBP
ArriVent BioPharma, Inc.23.11
-0.53-2.24%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
954.01MP/E (TTM)
-Basic EPS (TTM)
-4.15Dividend Yield
0%Recent Filings
8-K
AACR posters on firmonertinib, ARR-002
ArriVent announced two preclinical posters at the 2026 AACR Annual Meeting on firmonertinib's broad EGFR inhibition, including ex20ins mutants with strong antitumor activity, and ARR-002's superior efficacy in ovarian cancer models versus single-target ADCs. Firmonertinib supports its ongoing Phase 3 FURVENT trial. ARR-002 advances toward clinic. Data sharpen pipeline prospects.
8-K
Q4 2025 results: $313M cash
ArriVent BioPharma reported full-year 2025 net loss of $166.3 million, up from $80.5 million in 2024, driven by R&D expenses doubling to $153.4 million amid firmonertinib trials and ADC advances. Cash stands at $312.8 million, funding ops into 3Q 2027. Topline Phase 3 data for firmonertinib in EGFR exon 20 NSCLC hits mid-2026.
10-K
FY2025 results
ArriVent posted FY2025 net loss of $166.3M on $153.4M R&D spend, up from $80.5M loss and $79.0M R&D in 2024, fueled by firmonertinib trials like FURVENT ($48.7M) and early-stage ADCs ($55.5M). Q4 ramped R&D intensity while cash burn hit $160.6M operating outflow, offset by $203.1M equity raises including July's $80.5M offering—cash plus investments stood at $312.8M end-December, funding ops through 2026. No revenue yet. Clinical momentum builds: FURVENT enrollment complete, topline mid-2026; ALPACCA first patient dosed December. Pipeline accelerated. Yet trial delays could stall cash runway.
8-K
Q3 loss, strong cash, pipeline catalysts
ArriVent BioPharma reported Q3 2025 financials, posting a $131M net loss over nine months amid $121M R&D spend, including a $40M ARR-217 in-license. Cash stands at $305.4M, funding ops to mid-2027. Pipeline advances: firmonertinib Phase 1b success in PACC NSCLC, first ALPACCA Ph3 patient Q4 2025, FURVENT data early 2026. Hired commercial vet Brent Rice as CCO.
10-Q
Q3 FY2025 results
ArriVent posted a Q3 operating loss of $38.3M, up 58% y/y from $24.2M (derived), driven by R&D ramp to $32.2M from $20.1M as FURVENT Phase 3 and early-stage programs like Lepu ($40M upfront) accelerated; G&A rose to $6.1M. Net loss narrowed to $35.0M from $20.6M via $3.3M interest income, yielding $(0.83) diluted EPS on 41.9M shares—anti-dilution from options excluded. Cash swelled to $112.7M plus $193M investments ($305M total), fueled by $168M equity raises including July offering; $75M debt facility undrawn. Cash burn hit $130M YTD. Pipeline advances, yet clinical trial delays loom.
ABVC
ABVC Biopharma, Inc.
2.06-0.01
ACRV
Acrivon Therapeutics, Inc.
2.42-0.15
APLM
Apollomics Inc.
17.02+0.92
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
ARVN
Arvinas, Inc.
11.90-0.44
MNPR
Monopar Therapeutics Inc.
71.47-3.65
NUVB
Nuvation Bio Inc.
8.66+0.15
NUVL
Nuvalent, Inc.
102.63-2.34
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
TRAW
Traws Pharma, Inc.
2.20-0.04